Efficacy of GONB in Patients of Migraine

• Status: Completed
• Trial end date: 2022-08-31
• Target enrollment: 0
• Participant gender: All

Summary

The study was carried to determine the analgesic efficacy of greater occipital nerve block in patients of migraine. It was a randomised controlled which took place from april 2022 - october 2022. Fifty patients suffering from migraine were included in the study. Patients in Group G were given greater occipital nerve block (GONB) with lignocaine and dexamethasone under ultrasound guidance while those in Group S were given saline 0.9% as placebo. Pain score using Numeric Rating Scale and number of headache days was assessed at four,eight and twelve weeks after the procedure as a primary outcome. Total headache days were recorded as a secondary outcome.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Pain Medicine Department
• Treatments: Dexamethasone; Lidocaine

Criteria

Inclusion Criteria:

• Patients between 18 to 60 years

• diagnosed case of migraine

Exclusion Criteria:

• Patients with known allergies to local anaesthetics

• pregnancy

• history of cranial or cervical surgery

• head injury

• headaches secondary to medication overuse

• patients with uncontrolled systemic disease like blood pressure, diabetes mellitus

• hypo or hyperthyroidism

• patient who had already received GONB or botulinum toxin type A therapy within last 6 months

• major psychiatric disorder

• history of chronic pain syndromes